Skip to content
GERICLINICS

GeriQBank · Paper IV

Impulse control disorders

Moderate YieldAsked ×17-mark noteNeeds clinical review
Topic
Parkinsonism & Movement Disorders
Chapter
Neurology
Years asked
Not recorded in the source
Frequency
Set 1× in Paper IV (2009–2025)

As set in the university paper

  • Impulse control disorders.

    Paper IV · Cognition, Dementia, Delirium, Sleep & Psychogeriatrics · asked ×1 · 7-mark note · see in paper list

Answer framework

  1. Definition — DSM-5 grouping; dopaminergic treatment as the key cause in older people
  2. Clinical forms
  3. How common and why — prevalence; the reward-pathway mechanism; D3-preferring agonists; levodopa
  4. Risk factors — drug, person and disease
  5. Recognition — ask directly; warn before starting
  6. Management — prevention; first, second and third steps
  7. Older people — levodopa as the first choice with multimorbidity

An exam answer plan drawn from the detailed answer below. Use it to attempt the question first.

Detailed answer

Pro · free in beta
Attempt it firstOutline your answer as a 7-mark note before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer

Short revision answer

  • Impulse control disorders (DSM-5 disruptive, impulse-control and conduct disorders, considered alongside gambling disorder and binge eating) in older people are chiefly caused by dopaminergic drugs — especially dopamine agonists in Parkinson's disease, restless legs syndrome and prolactinoma.
  • Forms: pathological gambling, hypersexuality, compulsive shopping and binge eating, plus obsessive hobbying, punding and compulsive use of the medication itself.
  • Prevalence in Parkinson's is 2.6–34.8%, up to 39% with sustained agonist use and 58% in early-onset disease; 7–11% in restless legs. Agonists stimulate the reward (mesocorticolimbic) pathway as well as the motor one; D3-preferring agonists (pramipexole, ropinirole) carry the strongest signal. Levodopa can cause ICDs at about half the odds; untreated Parkinson's doesn't raise the risk.
  • Risk factors: drug (D3-selective agonist, higher dose, possibly immediate-release); person (male, under 65, depression or anxiety, nicotine, caffeine or alcohol use, family history of gambling); disease (earlier onset, longer duration, motor complications).
  • Recognition: ICDs are under-reported because of poor insight or shame — ask the patient and family directly at follow-up, and warn them before starting an agonist.
  • Management: prevent (identify those at risk, avoid D3-selective agonists in them, prefer extended-release forms, monitor). First, stop or control the behaviour and limit harm — reduce or gradually withdraw the agonist (watching for motor worsening and agonist withdrawal syndrome) or switch to a less D3-selective drug. Second, ICD-focused CBT with neurology and psychiatry. Third, subthalamic DBS or drugs tried in small studies (topiramate, valproate, zonisamide, naltrexone); SSRIs and antipsychotics give mixed results, and clozapine is risky.
  • In older people with multimorbidity, or when side effects of the alternatives are expected, levodopa is the appropriate first choice.

Condensed by GeriClinics from the detailed answer below, with no new facts added.

A. Definition

1.

Impulse control disorders (ICDs) are grouped in DSM-5 under disruptive, impulse-control and conduct disorders. Related behaviours classified elsewhere, such as gambling disorder (with addictive disorders) and binge eating (with eating disorders), are usually considered alongside them because they share high impulsivity.

2.

In older people the key cause to recognise is dopaminergic treatment, especially dopamine agonists in Parkinson's disease, and also in restless legs syndrome and prolactinoma.

B. Clinical forms

3.

Pathological gambling, hypersexuality, compulsive shopping and binge eating; related behaviours include obsessive hobbying, punding and compulsive use of the medication itself.

C. How common and why

4.

In Parkinson's disease, prevalence ranges from 2.6% to 34.8%, reaching 39% with sustained dopamine agonist use and 58% in early-onset disease; in restless legs syndrome it is 7–11%.

5.

Mechanism: the drugs stimulate dopamine receptors not only in the motor (nigrostriatal) pathway but also in the reward (mesocorticolimbic) pathway, which runs to the nucleus accumbens, amygdala and frontal cortex. Agonists that prefer D3 receptors, such as pramipexole and ropinirole, carry the strongest signal.

6.

Levodopa can also cause ICDs, but the odds are about half those with dopamine agonists. Parkinson's disease itself, before treatment, does not seem to raise the risk.

D. Risk factors

7.

Drug: type of agonist (D3-selective), higher daily dose, and possibly immediate-release rather than extended-release forms.

8.

Person: male sex, younger age (under 65), history of depression or anxiety, use of nicotine, caffeine or alcohol, and a family history of gambling.

9.

Disease: earlier onset, longer duration and motor complications.

E. Recognition

10.

ICDs are under-reported because people lack insight or feel ashamed, so ask the patient and family directly at follow-up.

11.

Warn the person and carers about ICDs before starting a dopamine agonist.

F. Management

12.

Prevention: identify those at risk, avoid the most D3-selective agonists in them, inform patients and carers, prefer extended-release forms, and monitor regularly.

13.

First step: the priority is to stop or control the behaviour and minimise harm. Reduce the dopaminergic dose or withdraw the agonist gradually, watching for worsening motor symptoms and dopamine agonist withdrawal syndrome; or switch to a less D3-selective agonist.

14.

Second step: cognitive behavioural therapy focused on the ICD, with neurology and psychiatry working together.

15.

Third step, if needed: subthalamic deep brain stimulation (results inconsistent) or drugs tried in small numbers of patients (topiramate, valproate, zonisamide, naltrexone). SSRIs and antipsychotics have given mixed results; clozapine helped a few but has serious side effects.

G. Older people

16.

Levodopa is the appropriate first choice when there is multimorbidity or when side effects of the alternatives are expected, which applies to many older people with Parkinson's disease.

How was your recall?

Rating marks the question complete. “Need another pass” also adds it to your bookmarks.

References

Written in GeriClinics' own words from the sources above, and checked against them. Not yet clinically reviewed.

Spotted an error or something out of date?Report a problem with this page